Fair Value Measurements - Additional Information (Detail)	12 Months Ended
	Sep. 30, 2016 USD ($) shares	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2011 shares	Jan. 31, 2013 shares	Dec. 31, 2012 shares	Jun. 30, 2010 shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants outstanding	528,181
Non-cash gain (loss) from change in fair value of the derivative liability | $	$ (293,072)	$ 2,684,712	$ (5,821,796)
Contingent consideration obligations | $	$ 0	5,862,464
Ablaris Therapeutics
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants outstanding	500,000
Non-cash gain (loss) from change in fair value of the derivative liability | $	$ (7,950)	$ 184,555	$ (211,860)
Duration of exchange rights	7 years
Exchange right convertible conversion ratio	0.01
Number of exchange right sold				675,000
2010 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants issued to acquire Common Stock							329,649
Warrants cancelled upon expiration	24,324
2012 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants issued to acquire Common Stock						912,543
Warrants outstanding	265,161
2013 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants issued to acquire Common Stock					833,530
Warrants outstanding	12,123